Fbxw7-associated Drug Resistance is Reversed by Induction of Terminal Differentiation in Murine Intestinal Organoid Culture

Overview

Journal Mol Ther Methods Clin Dev

Publisher Cell Press

Date 2016 Apr 26

PMID 27110583

Citations 21

Authors

Federica Lorenzi

Roya Babaei-Jadidi

Jonathan Sheard

Bradley Spencer-Dene

Abdolrahman S Nateri

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is one of the top three cancer-related causes of death worldwide. FBXW7 is a known tumor-suppressor gene, commonly mutated in CRC and in a variety of other epithelial tumors. Low expression of FBXW7 is also associated with poor prognosis. Loss of FBXW7 sensitizes cancer cells to certain drugs, while making them more resistant to other types of chemotherapies. However, is not fully understood how epithelial cells within normal gut and primary tumors respond to potential cancer therapeutics. We have studied genetically engineered mice in which the fbxw7 gene is conditionally knocked-out in the intestine (fbxw7(∆G)). To further investigate the mechanism of Fbxw7-action, we grew intestinal crypts from floxed-fbxw7 (fbxw7(fl/fl)) and fbxw7(ΔG) mice, in a Matrigel-based organoid (mini-gut) culture. The fbxw7(ΔG) organoids exhibited rapid budding events in the crypt region. Furthermore, to test organoids for drug response, we exposed day 3 intestinal organoids from fbxw7(fl/fl) and fbxw7(∆G) mice, to various concentrations of 5-fluorouracil (5-FU) for 72 hours. 5-FU triggers phenotypic differences in organoids including changing shape, survival, resistance, and death. 5-FU however, rescues the drug-resistance phenotype of fbxw7(ΔG) through the induction of terminal differentiation. Our results support the hypothesis that a differentiating therapy successfully targets FBXW7-mutated CRC cells.

Citing Articles

FBXW7 and human tumors: mechanisms of drug resistance and potential therapeutic strategies.

Wang W, Jiang K, Liu X, Li J, Zhou W, Wang C Front Pharmacol. 2023; 14:1278056.

PMID: 38027013 PMC: 10680170. DOI: 10.3389/fphar.2023.1278056.

Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7.

Baxter J, Brough R, Krastev D, Song F, Sridhar S, Gulati A Mol Oncol. 2023; 18(2):369-385.

PMID: 37866880 PMC: 10850818. DOI: 10.1002/1878-0261.13537.

Activation of the integrated stress response is a vulnerability for multidrug-resistant FBXW7-deficient cells.

Sanchez-Burgos L, Navarro-Gonzalez B, Garcia-Martin S, Sirozh O, Mota-Pino J, Fueyo-Marcos E EMBO Mol Med. 2022; 14(9):e15855.

PMID: 35861150 PMC: 9449593. DOI: 10.15252/emmm.202215855.

The Potential Role of Genomic Signature in Stage II Relapsed Colorectal Cancer (CRC) Patients: A Mono-Institutional Study.

Roberto M, Arrivi G, Pilozzi E, Montori A, Balducci G, Mercantini P Cancer Manag Res. 2022; 14:1353-1369.

PMID: 35418781 PMC: 9000544. DOI: 10.2147/CMAR.S342612.

Application Progress of Organoids in Colorectal Cancer.

Luo L, Ma Y, Zheng Y, Su J, Huang G Front Cell Dev Biol. 2022; 10:815067.

PMID: 35273961 PMC: 8902504. DOI: 10.3389/fcell.2022.815067.

References

Mao J, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama K . Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature. 2004; 432(7018):775-9. DOI: 10.1038/nature03155. View

Song Y, Zhou X, Bai W, Ma X . FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein. Tumour Biol. 2015; 36(6):4197-202. DOI: 10.1007/s13277-015-3056-4. View

Durand A, Donahue B, Peignon G, Letourneur F, Cagnard N, Slomianny C . Functional intestinal stem cells after Paneth cell ablation induced by the loss of transcription factor Math1 (Atoh1). Proc Natl Acad Sci U S A. 2012; 109(23):8965-70. PMC: 3384132. DOI: 10.1073/pnas.1201652109. View

Fodde R, Brabletz T . Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007; 19(2):150-8. DOI: 10.1016/j.ceb.2007.02.007. View

Li N, Lorenzi F, Kalakouti E, Normatova M, Babaei-Jadidi R, Tomlinson I . FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15. Oncotarget. 2015; 6(11):9240-56. PMC: 4496214. DOI: 10.18632/oncotarget.3284. View

Barker N, van Es J, Kuipers J, Kujala P, van den Born M, Cozijnsen M . Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature. 2007; 449(7165):1003-7. DOI: 10.1038/nature06196. View

van de Wetering M, Francies H, Francis J, Bounova G, Iorio F, Pronk A . Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015; 161(4):933-45. PMC: 6428276. DOI: 10.1016/j.cell.2015.03.053. View

Sato T, Clevers H . Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science. 2013; 340(6137):1190-4. DOI: 10.1126/science.1234852. View

Grim J, Knoblaugh S, Guthrie K, Hagar A, Swanger J, Hespelt J . Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. Mol Cell Biol. 2012; 32(11):2160-7. PMC: 3372235. DOI: 10.1128/MCB.00305-12. View

10.

Kemp Z, Rowan A, Chambers W, Wortham N, Halford S, Sieber O . CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability. Cancer Res. 2005; 65(24):11361-6. DOI: 10.1158/0008-5472.CAN-05-2565. View

11.

Stintzing S . Management of colorectal cancer. F1000Prime Rep. 2015; 6:108. PMC: 4229728. DOI: 10.12703/P6-108. View

12.

Welcker M, Clurman B . FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2007; 8(2):83-93. DOI: 10.1038/nrc2290. View

13.

Cremona C, Sancho R, Diefenbacher M, Behrens A . Fbw7 and its counteracting forces in stem cells and cancer: Oncoproteins in the balance. Semin Cancer Biol. 2015; 36:52-61. DOI: 10.1016/j.semcancer.2015.09.006. View

14.

. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407):330-7. PMC: 3401966. DOI: 10.1038/nature11252. View

15.

Ratineau C, Petry M, Mutoh H, Leiter A . Cyclin D1 represses the basic helix-loop-helix transcription factor, BETA2/NeuroD. J Biol Chem. 2002; 277(11):8847-53. DOI: 10.1074/jbc.M110747200. View

16.

Cheng Y, Li G . Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer Metastasis Rev. 2011; 31(1-2):75-87. DOI: 10.1007/s10555-011-9330-z. View

17.

Sjoblom T, Jones S, Wood L, Parsons D, Lin J, Barber T . The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314(5797):268-74. DOI: 10.1126/science.1133427. View

18.

ONeil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C . FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007; 204(8):1813-24. PMC: 2118656. DOI: 10.1084/jem.20070876. View

19.

Matano M, Date S, Shimokawa M, Takano A, Fujii M, Ohta Y . Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med. 2015; 21(3):256-62. DOI: 10.1038/nm.3802. View

20.

Sato T, van Es J, Snippert H, Stange D, Vries R, van den Born M . Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature. 2010; 469(7330):415-8. PMC: 3547360. DOI: 10.1038/nature09637. View